Q3/2022 9/30/2022 EPS -0.210 ZacksConsensus -0.230 ActVsEst 0.020 - Beat
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Wall Street Horizon
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2022 on February 8, 2023PR Newswire
- Viking Therapeutics, Inc. (NASDAQ: VKTX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Viking Therapeutics, Inc. (NASDAQ: VKTX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Viking Therapeutics Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)PR Newswire
- Viking Therapeutics sues Ascletis Pharma for stealing trade secrets [Seeking Alpha]Seeking Alpha
VKTX
Earnings
- 7/27/22 - Miss
VKTX
Analyst Actions
- 12/20/22 - Maxim Group
VKTX
Sec Filings
- 1/17/23 - Form 4
- 1/4/23 - Form 4
- 1/4/23 - Form 4
- VKTX's page on the SEC website